5H

Hangzhou Tigermed Consulting Co LtdMUN Hangzhou Tigermed Stock Report

Last reporting period 30 Jun, 2024

Updated 08 Nov, 2024

Last price

Market cap $B

5.25

Middle

Exchange

XMUN - Boerse Muenchen

5HZ1.MU Stock Analysis

5H

Uncovered

Hangzhou Tigermed Consulting Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

29/100

Low score

Market cap $B

5.25

Dividend yield

1.17 %

Shares outstanding

864.95 B

Hangzhou Tigermed Consulting Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Hangzhou, Zhejiang and currently employs 8,326 full-time employees. The company went IPO on 2012-08-17. Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The firm operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The firm conducts its businesses in the domestic and overseas markets.

View Section: Eyestock Rating